美国“南方哈佛”Mazzocchi团队成立肿瘤药敏公司:Known Medicine

发布日期:2020-08-17  浏览次数:468

      21世纪,人类健康正在遭受各种突发疾病和慢性病的侵袭。美国疫情已造成17余万死亡,相比恶性肿瘤的形式更加严峻,去年1年美国癌症死亡人数超60万。近期,来自具有“南方哈佛”之称的美国维克森林大学(Wake Forest University生物医学工程学系的Mazzocchi 博士在疫情期间成立了一家公司——Known Medicine,利用生物医学工程技术,通过体外药敏筛查,帮助每个肿瘤患者快速寻找最佳治疗决策


 一、每个肿瘤患者都需要最佳治疗决策

Known Medcine :Cancer care has made enormous strides over the years. Despite this proliferation of new treatments, oncologists still rely on certain presumptions to pick the best option for their patients. Known Medicine wants to take away that guesswork. Make no mistake—doctors are the best people to be making such decisions, but they’re “definitely making a best guess,” co-founder and CEO Andrea Mazzocchi said.


      中科普瑞昇:肿瘤医生往往需要借助生物标志物、病理、临床路径来为患者制定用药方案,而当患者没有明确的生物标志物,或对预期方案没有疗效时,医生和患者都会面临巨大挑战。20202月成立的Known Medcine公司旨在通过建立体外肿瘤模型来帮助医生“更好的决策”,这与中科普瑞昇的事业不谋而合,中科普瑞昇秉承我国中医“同病异治、异病同治”的理念,采用“老药新用”的手段,通过PDCPDOPDX等肿瘤模型,帮助每个肿瘤患者精准选药,使得临床决策不受生物标志物和特定驱动基因的限制,让每个肿瘤患者都能用上适合自己的疗法,这对肿瘤的治疗来说是很有必要的。

 

二、体外构建肿瘤模型是关键

      Known Medcine :Here’s how it works: Known Medicine receives a tumor sample from a hospital and breaks it down into several mini-tumors in its lab. It then doses each model with different cancer drugs and drug combinations to see what works best for each patient.

      “We want to know what the longer-term effects of these drugs are, beyond just the five-day assay we run,” Skelly said, adding that the company could use machine learning to find cells that are pre-apoptotic—on their way to death—that would show up as alive in its test, but would respond to treatment over time.



      中科普瑞昇:目前肿瘤用药预测模型代表性的有类器官、PDXmini-tumor、原代细胞等,这些技术转向临床需要同时具备以下几个要素:1)快速,肿瘤医生在患者病理确诊后或复发后需要第一时间制定治疗方案,这就要求利用模型支持治疗决策的时间越短越好,目前临床可接收的周期为1-2周;2)通量高,所谓通量即在单个周期内检测的药物数量,只有检测的药物足够多,才能应对肿瘤复杂多变的特性,帮助患者及时锁定可选择的有效方案;3)成功率高,肿瘤体外建模需要获取患者的肿瘤样本,由于肿瘤患者进行临床取样的机会有限,我们认为只有成功率高于90%时才适合临床推广;4)可测量,除了需要可供评价体外药敏的指标,如药物浓度、细胞凋亡、肿瘤大小等,还需要模型本身在评价药物时具有稳定性、同步性、可重复性。


三、精准用药策略有讲究

      Known MedicineKnown Medicine’s approach focuses on the FDA-approved standard of care for each specific cancer. It could be particularly helpful in suggesting the off-label use of different chemotherapies that “are not so obvious to find,” Mazzocchi said. The company works closely with oncologists at Wake Forest, to stay on the “cutting edge” of cancer treatment and make sure it’s not missing any possible options.



      “In the longer term, that will likely also involve partnerships and discovering new treatments for patients. That’s one of our long-term visions,” Skelly said. “But any way we can make sure patients are treated in the best possible way—that is what we’re chasing after, first and foremost.”



      中科普瑞昇:Known Medicine公司首先瞄准了FDA推荐的肿瘤治疗药物和方案,帮助患者在现有药物里作出最佳选择,然后再利用后续培养体系筛选新药和新的组合方案。中科普瑞昇经过5年多的临床实践发现,对于早期或初诊的肿瘤患者,可以先进行10-20个临床常用药物的检测,此时往往是抗癌最佳治疗时机,主要帮助患者提高首次治疗成功率,延迟复发时间窗或尽量避免复发;对于中晚期或复发难治型肿瘤患者,采用大规模药物筛选的策略,一次检测上百个药物,来提高有效药物发掘成功率,包括靶向药物、中药单体、临床试验药物、组合方案等。


四、未来可期

      Known MedicineMoving forward, the company hopes to develop a testing kit for research use, and then one for clinical use, Mazzocchi said. The goal is to put its product in every hospital or cancer clinic, not just to help patients, but also to collect data to eventually be used in drug discovery.

“In the future, we will be able to look at a picture of a [mini-tumor] that’s been treated with a drug and tell you whether that treatment is working or not,” Skelly said.

      中科普瑞昇:肿瘤建模和个体化治疗还将推动新药精准研发、医疗大数据、肿瘤治疗模式的发展,也许若干年后任何一个肿瘤患者都能够在很短的时间内获取一套适合自己的治疗模式,可能是几小时,也可能只需要几分钟...

      随着国内外从事以肿瘤组织发展不同模型来进行药物筛选的机构不断增加,相信肿瘤精准治疗将发生质的飞跃,这也是生物医药行业在数据信息时代的发展趋势

      中科普瑞昇首创HDS肿瘤精准用药检测技术体系,具有快速、精准、通量高等特点,正在建设中国可再生原代细胞生命银行,欢迎咨询合作!